Page 9 - Decision Diagnostics News Today : Breaking News, Live Updates & Top Stories | Vimarsana

CEO charged in alleged COVID-19 fraud scheme MarketWatch 12/19/2020 Claudia Assis © Thomson Reuters A vial of the Pfizer vaccine against the coronavirus disease (COVID-19) used at The Reservoir nursing facility is shown in West Hartford, Connecticut, U.S., December 18, 2020. Stephen Dunn/Pool via REUTERS The Justice Department said late Friday that a federal grand jury has indicted a California chief executive for allegedly concocting a scheme to defraud investors with false claims about a COVID-19 test. Popular Searches That led to millions of dollars in investors losses...

December 18, 2020 On Thursday in the Southern District of New York, the Securities and Exchange Commission (SEC) filed a complaint against Keith Berman and Decision Diagnostics Corp. (DECN), alleging that the defendants made false and misleading public statements in the spring that they had developed a “break-through” finger-pricking device to test for the novel coronavirus when they actually had not finished the product nor even developed a prototype. In mid-February, Berman, president and CEO of biotechnology company DECN, learned of the location of DECN’s manufacturing site for its ...

Decision Diagnostics Corp.: DECN Comments on Recent Legal Filings by Federal Agencies LOS ANGELES, CA / ACCESSWIRE / December 18, 2020 / Decision Diagnostics Corp. (OTC PINK:DECN) www.decisiondiagnostics.co, a leading manufacturer and worldwide distributor of diabetic test strips engineered to operate on legacy glucose meters through its subsidiary Pharma Tech Solutions, Inc., as well as the designer and manufacturer of the GenViro! Covid-19 Swift Kit testing kits, hereby confirms two recent legal filings by separate agencies of the Federal government regarding DECN and its CEO Keith Berman c...

DOJ and SEC Pursue Decision Diagnostics CEO on COVID-19 Testing Fraud Posted on 12/19/2020 The U.S. Justice Department revealed that a federal grand jury has indicted a California chief executive for allegedly concocting a scheme to defraud investors with false claims about a COVID-19 test. The false claim led to investor losses. Keith Berman, 67, the CEO of Decision Diagnostics Inc., was charged with one count of securities fraud and one count of making false statements, the DOJ said. The SEC temporarily suspended trading in Decision Diagnostics’ securities on April 23, 2020. The complaint...

SEC Charges Biotech Company and CEO with Fraud Concerning COVID-19 Blood Testing Device Washington, D.C.--(Newsfile Corp. - December 18, 2020) - The Securities and Exchange Commission today announced charges against California-based biotechnology company Decision Diagnostics Corp. and its CEO, Keith Berman, with making false and misleading claims in numerous press releases that the company had developed a working, break-through technology that could accurately detect Covid-19 through a quick blood test. The SEC temporarily suspended trading in Decision Diagnostics' securities on April 23, 20...